Sysmex Corporation (FRA:0YX)

Market Cap	5.03B
Revenue (ttm)	2.87B
Net Income (ttm)	268.87M
Shares Out	n/a
EPS (ttm)	0.43
PE Ratio	18.71
Forward PE	n/a
Dividend	0.21 (2.51%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	231
Open	7.70
Previous Close	8.10
Day's Range	7.70 - 7.70
52-Week Range	7.70 - 19.70
Beta	n/a
RSI	43.39
Earnings Date	Feb 12, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Laboratory Analytical Instruments
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0YX

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY